Coherus BioSciences (NASDAQ:CHRS) Releases Earnings Results, Misses Expectations By $0.34 EPS

Coherus BioSciences (NASDAQ:CHRS - Get Free Report) issued its earnings results on Monday. The biotechnology company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.34), Zacks reports. The firm had revenue of $54.14 million during the quarter, compared to the consensus estimate of $43.88 million.

Coherus BioSciences Trading Up 6.2 %

Shares of CHRS traded up $0.06 on Friday, reaching $0.95. 1,085,299 shares of the company's stock were exchanged, compared to its average volume of 1,950,428. The stock has a market capitalization of $109.63 million, a P/E ratio of -11.83 and a beta of 0.92. The business has a 50 day moving average price of $1.22 and a two-hundred day moving average price of $1.18. Coherus BioSciences has a 12 month low of $0.66 and a 12 month high of $2.64.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. HC Wainwright restated a "buy" rating and issued a $7.00 target price on shares of Coherus BioSciences in a research report on Tuesday. Robert W. Baird upped their price target on shares of Coherus BioSciences from $4.00 to $6.00 and gave the company an "outperform" rating in a research report on Thursday, December 5th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $5.38.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.